Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G

Bradley J. Catalone, Shendra R. Miller, Mary Lee Ferguson, Daniel Malamud, Tina Kish-Catalone, Nina J. Thakkar, Fred C. Krebs, Mary K. Howett, Brian Wigdahl

Research output: Contribution to journalArticle

Abstract

C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised of a buffered equimolar mixture of two amphoteric, surface-active agents: an alkyl amine oxide (C14AO) and an alkyl betaine (C16B). Studies of long-term in vitro exposure to C31G and its constituents have suggested that the components of C31G may contribute differentially to its toxicity and efficacy. In the present studies, in vitro assays of cytotoxicity and anti-HIV-1 activity demonstrated that C16B was slightly less cytotoxic compared to either C31G or C14AO, whereas the anti-HIV-1 activities of C31G and its individual constituents were similar. In the murine model of cervicovaginal microbicide toxicity, in vivo exposure to C14AO resulted in severe cervical inflammation followed by a delayed disruption of the columnar epithelium. In contrast, exposure to C16B caused severe cervical epithelial disruption and a secondary, less intense inflammatory response. These results demonstrate that (i) there are both mechanistic and temporal differences in toxicity associated with the components of C31G not necessarily predicted by in vitro assessments of cytotoxicity and (ii) contributions of each component to the anti-HIV-1 activity of C31G appear to be equal. In addition, these findings indicate that direct and indirect mechanisms of in vivo toxicity can be observed as separate but interrelated events. These results provide further insight into the activity of C31G, as well as mechanisms potentially associated with microbicide toxicity.

Original languageEnglish (US)
Pages (from-to)430-437
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume59
Issue number8
DOIs
StatePublished - Sep 2005

Fingerprint

HIV-1
Inflammation
Anti-Infective Agents
Betaine
C 31G
Surface-Active Agents
Oxides
Amines
Epithelium
Safety
In Vitro Techniques

Keywords

  • Amine oxide
  • Betaine
  • C31G
  • HIV-1
  • Microbicide
  • Surfactant
  • Swiss Webster mouse model

ASJC Scopus subject areas

  • Pharmacology

Cite this

Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. / Catalone, Bradley J.; Miller, Shendra R.; Ferguson, Mary Lee; Malamud, Daniel; Kish-Catalone, Tina; Thakkar, Nina J.; Krebs, Fred C.; Howett, Mary K.; Wigdahl, Brian.

In: Biomedicine and Pharmacotherapy, Vol. 59, No. 8, 09.2005, p. 430-437.

Research output: Contribution to journalArticle

Catalone, BJ, Miller, SR, Ferguson, ML, Malamud, D, Kish-Catalone, T, Thakkar, NJ, Krebs, FC, Howett, MK & Wigdahl, B 2005, 'Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G', Biomedicine and Pharmacotherapy, vol. 59, no. 8, pp. 430-437. https://doi.org/10.1016/j.biopha.2005.07.008
Catalone, Bradley J. ; Miller, Shendra R. ; Ferguson, Mary Lee ; Malamud, Daniel ; Kish-Catalone, Tina ; Thakkar, Nina J. ; Krebs, Fred C. ; Howett, Mary K. ; Wigdahl, Brian. / Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. In: Biomedicine and Pharmacotherapy. 2005 ; Vol. 59, No. 8. pp. 430-437.
@article{4be0095915724b96bb078bc2843f9d09,
title = "Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G",
abstract = "C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised of a buffered equimolar mixture of two amphoteric, surface-active agents: an alkyl amine oxide (C14AO) and an alkyl betaine (C16B). Studies of long-term in vitro exposure to C31G and its constituents have suggested that the components of C31G may contribute differentially to its toxicity and efficacy. In the present studies, in vitro assays of cytotoxicity and anti-HIV-1 activity demonstrated that C16B was slightly less cytotoxic compared to either C31G or C14AO, whereas the anti-HIV-1 activities of C31G and its individual constituents were similar. In the murine model of cervicovaginal microbicide toxicity, in vivo exposure to C14AO resulted in severe cervical inflammation followed by a delayed disruption of the columnar epithelium. In contrast, exposure to C16B caused severe cervical epithelial disruption and a secondary, less intense inflammatory response. These results demonstrate that (i) there are both mechanistic and temporal differences in toxicity associated with the components of C31G not necessarily predicted by in vitro assessments of cytotoxicity and (ii) contributions of each component to the anti-HIV-1 activity of C31G appear to be equal. In addition, these findings indicate that direct and indirect mechanisms of in vivo toxicity can be observed as separate but interrelated events. These results provide further insight into the activity of C31G, as well as mechanisms potentially associated with microbicide toxicity.",
keywords = "Amine oxide, Betaine, C31G, HIV-1, Microbicide, Surfactant, Swiss Webster mouse model",
author = "Catalone, {Bradley J.} and Miller, {Shendra R.} and Ferguson, {Mary Lee} and Daniel Malamud and Tina Kish-Catalone and Thakkar, {Nina J.} and Krebs, {Fred C.} and Howett, {Mary K.} and Brian Wigdahl",
year = "2005",
month = "9",
doi = "10.1016/j.biopha.2005.07.008",
language = "English (US)",
volume = "59",
pages = "430--437",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "8",

}

TY - JOUR

T1 - Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G

AU - Catalone, Bradley J.

AU - Miller, Shendra R.

AU - Ferguson, Mary Lee

AU - Malamud, Daniel

AU - Kish-Catalone, Tina

AU - Thakkar, Nina J.

AU - Krebs, Fred C.

AU - Howett, Mary K.

AU - Wigdahl, Brian

PY - 2005/9

Y1 - 2005/9

N2 - C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised of a buffered equimolar mixture of two amphoteric, surface-active agents: an alkyl amine oxide (C14AO) and an alkyl betaine (C16B). Studies of long-term in vitro exposure to C31G and its constituents have suggested that the components of C31G may contribute differentially to its toxicity and efficacy. In the present studies, in vitro assays of cytotoxicity and anti-HIV-1 activity demonstrated that C16B was slightly less cytotoxic compared to either C31G or C14AO, whereas the anti-HIV-1 activities of C31G and its individual constituents were similar. In the murine model of cervicovaginal microbicide toxicity, in vivo exposure to C14AO resulted in severe cervical inflammation followed by a delayed disruption of the columnar epithelium. In contrast, exposure to C16B caused severe cervical epithelial disruption and a secondary, less intense inflammatory response. These results demonstrate that (i) there are both mechanistic and temporal differences in toxicity associated with the components of C31G not necessarily predicted by in vitro assessments of cytotoxicity and (ii) contributions of each component to the anti-HIV-1 activity of C31G appear to be equal. In addition, these findings indicate that direct and indirect mechanisms of in vivo toxicity can be observed as separate but interrelated events. These results provide further insight into the activity of C31G, as well as mechanisms potentially associated with microbicide toxicity.

AB - C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised of a buffered equimolar mixture of two amphoteric, surface-active agents: an alkyl amine oxide (C14AO) and an alkyl betaine (C16B). Studies of long-term in vitro exposure to C31G and its constituents have suggested that the components of C31G may contribute differentially to its toxicity and efficacy. In the present studies, in vitro assays of cytotoxicity and anti-HIV-1 activity demonstrated that C16B was slightly less cytotoxic compared to either C31G or C14AO, whereas the anti-HIV-1 activities of C31G and its individual constituents were similar. In the murine model of cervicovaginal microbicide toxicity, in vivo exposure to C14AO resulted in severe cervical inflammation followed by a delayed disruption of the columnar epithelium. In contrast, exposure to C16B caused severe cervical epithelial disruption and a secondary, less intense inflammatory response. These results demonstrate that (i) there are both mechanistic and temporal differences in toxicity associated with the components of C31G not necessarily predicted by in vitro assessments of cytotoxicity and (ii) contributions of each component to the anti-HIV-1 activity of C31G appear to be equal. In addition, these findings indicate that direct and indirect mechanisms of in vivo toxicity can be observed as separate but interrelated events. These results provide further insight into the activity of C31G, as well as mechanisms potentially associated with microbicide toxicity.

KW - Amine oxide

KW - Betaine

KW - C31G

KW - HIV-1

KW - Microbicide

KW - Surfactant

KW - Swiss Webster mouse model

UR - http://www.scopus.com/inward/record.url?scp=25644452139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25644452139&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2005.07.008

DO - 10.1016/j.biopha.2005.07.008

M3 - Article

VL - 59

SP - 430

EP - 437

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 8

ER -